Abstract
It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity. Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamicin are primarily cochleotoxic. Cochlear damage can produce permanent hearing loss, and damage to the vestibular apparatus results in dizziness, ataxia, and/or nystagmus. Aminoglycosides appear to generate free radicals within the inner ear, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss. Two mutations in the mitochondrial 12S ribosomal RNA gene have been previously reported to predispose carriers to aminoglycosideinduced ototoxicity. As aminoglycosides are indispensable agents both in the treatment of infections and Meniere ’ s disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity. Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides. In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.
Keywords: Aminoglycosides, ototoxicity
Current Pharmaceutical Design
Title: Aminoglycoside-Induced Ototoxicity
Volume: 13 Issue: 1
Author(s): Erol Selimoglu
Affiliation:
Keywords: Aminoglycosides, ototoxicity
Abstract: It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity. Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamicin are primarily cochleotoxic. Cochlear damage can produce permanent hearing loss, and damage to the vestibular apparatus results in dizziness, ataxia, and/or nystagmus. Aminoglycosides appear to generate free radicals within the inner ear, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss. Two mutations in the mitochondrial 12S ribosomal RNA gene have been previously reported to predispose carriers to aminoglycosideinduced ototoxicity. As aminoglycosides are indispensable agents both in the treatment of infections and Meniere ’ s disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity. Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides. In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.
Export Options
About this article
Cite this article as:
Selimoglu Erol, Aminoglycoside-Induced Ototoxicity, Current Pharmaceutical Design 2007; 13 (1) . https://dx.doi.org/10.2174/138161207779313731
DOI https://dx.doi.org/10.2174/138161207779313731 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects
Anti-Infective Agents in Medicinal Chemistry Editorial [ NeuroAIDS: A Neuroscience Problem with Global Impact ]
Current HIV Research Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Endocrine, Metabolic & Immune Disorders - Drug Targets IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Clinical Trials with Intracerebral Convection-Enhanced Delivery of Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials A Hybrid Approach for Sub-Acute Ischemic Stroke Lesion Segmentation Using Random Decision Forest and Gravitational Search Algorithm
Current Medical Imaging Structure-Activity Relationships of Histamine H1-Receptor Agonists
Mini-Reviews in Medicinal Chemistry Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index
Current Pharmaceutical Design Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery The Experience of Combining Agents, Specially Triptans and Non Steroidal Anti-Inflammatory Drugs, for the Acute Treatment of Migraine - A Review
Recent Patents on CNS Drug Discovery (Discontinued) Epidemiological Review of Gonococcal Infection
Current Women`s Health Reviews Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy Antifungal Proteins: Potent Candidate for Inhibition of Pathogenic Fungi
Current Bioactive Compounds Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design